Time called on Pfizer–AstraZeneca deal


Pfizer’s pursuit of a pharmaceutical megamerger with AstraZeneca (AZ) has concluded with the US giant withdrawing its final offer two hours before the deadline set by the UK’s takeover rules.

The City Code on Takeovers and Mergers allows Pfizer to make a new approach to AZ after a six month cooling off period, or AZ can invite Pfizer to negotiate after three months. Given the Anglo-Swedish firm’s steadfast refusal to entertain Pfizer’s advances, the latter option seems unlikely. ‘We welcome the opportunity to continue building on the momentum we have already demonstrated as an independent company,’ AZ’s chairman Leif Johansson said in a statement after the withdrawal.

Pfizer, in its turn, is leaving the door open. ‘We continue to believe that our final proposal was compelling and represented full value for AstraZeneca based on the information that was available to us’ said chief executive Ian Read in the withdrawal statement. The value and attactiveness of any new offer will depend strongly on how well AZ lives up to predictions about forthcoming drugs made by the board to justify its refusal of this deal. 


Related Content

Pfizer presses hard for AstraZeneca deal

14 May 2014 Business

news image

Executives face down international controversy over tax schemes and previous post-merger record

Pfizer courts AstraZeneca megamerger

29 April 2014 Business

news image

AZ rebuffs public dealmongering

Most Read

Self-cleaning sensors see the light

23 January 2015 Research

news image

Overcoming electrode fouling in biomedical and environmental detectors

Alkali metal explosion explained

26 January 2015 Research

news image

High-speed cameras help re-examine the chemistry behind a classic classroom demonstration

Most Commented

Alkali metal explosion explained

26 January 2015 Research

news image

High-speed cameras help re-examine the chemistry behind a classic classroom demonstration

What we mean when we talk about bonds

29 January 2015 Comments

news image

Santiago Alvarez delves into the debates and disagreements that surround one of chemistry's most fundamental concepts